Previous 10 | Next 10 |
2023-07-12 09:45:03 ET Summary Cassava Sciences' results for mild Alzheimer's disease are better than placebo at 12 months but little better beyond this. Thus, there is no compelling reason to invest in the stock. Simufilam may help maintain cognition in those with mild cognitive ...
2023-07-09 10:48:14 ET Summary Cassava Sciences continues to show promising data. Cassava Sciences Simufilam shows a 205% improvement compared to placebo in the most recent study. Recently approved drugs by Biogen have competitive data with Simufilam by Cassava Sciences. B...
2023-07-07 11:24:23 ET Summary Cassava stock crashed in reaction to top-line data from a Phase 2 trial. Both treatment and placebo groups showed little decline on a cognitive test. Market doesn’t realize patient and design characteristics differ from past studies. ...
2023-07-06 12:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-07-05 15:05:31 ET Summary Cassava Sciences' Alzheimer's drug, simufilam, reduced cognitive decline by 38% in a small study, but the results were not statistically significant, raising doubts about its efficacy. Despite a cash reserve of $187.5 million, Cassava's Q1 2023 net l...
2023-07-05 13:00:26 ET Gainers: Mullen Automotive ( MULN ) +47% . iMedia Brands ( IMBI ) +45% . LightPath Technologies ( LPTH ) +32% . Cibus ( CBUS ) +34% . Impel Pharmaceuticals ( IMPL ) +29% . BioXcel Therapeutics ( BTAI ...
2023-07-05 11:44:52 ET Shares of Cassava Sciences (NASDAQ: SAVA) were down more than 14% as of 11:30 a.m. ET on Wednesday after the clinical-stage biotech company announced so-so results for an Alzheimer's disease therapy. The stock is down more than 28% so far this year. Ca...
2023-07-05 09:41:27 ET Cassava Sciences ( NASDAQ: SAVA ) announced Wednesday that its lead candidate simufilam slowed cognitive decline by 38% compared to placebo in a small proof-of-concept study for patients with mild-to-moderate Alzheimer’s disease. The U.S.-based tr...
Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease. Drug Effects Favored Mild Alzheimer’s Disease. In Mild Alzheimer’s, Simufilam Improved Cognition Scores Over 6 Months. In Mild...
Overactive mTOR Plays a Key Role in Aging and Alzheimer’s Disease. Simufilam Suppresses Overactive mTOR, Suggesting a Beneficial Drug Effect. Research is Published in Frontiers in Aging , a Peer-reviewed Journal. AUSTIN, Texas, June 27, 2023 (GLO...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...